HIV-1 reactivation, BRD4 inhibitor, Triazolopyridine derivatives, Latency-reversing agents (LRAs)
HIV-1, BRD4 inhibitor, triazolopyridine derivatives, Latency-reversing agent (LRA), Structure-activity relationship (SAR)